Pet measurements of cAMP-mediated phosphodiesterase-4 with (R)-[11C]rolipram

Current Radiopharmaceuticals

Volumn 4, Issue 1, 2011, Pages 44-58

  Kenk, Miran ^a,b   Thomas, Adam ^a,b   Lortie, Mireille ^a   dekemp, Rob ^a,b   Beanlands, Rob S ^a,b   Dasilva, Jean N ^a,b  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Altered PDE4 in animal models; Cyclic adenosine monophosphate; PDE4 imaging; Positron emission tomography; Rolipram specific binding; Signal transduction PET tracers

Indexed keywords

ADENYLATE CYCLASE; ANTHRACYCLINE; BRAIN DERIVED NEUROTROPHIC FACTOR; CARBON 11; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; GUANINE NUCLEOTIDE BINDING PROTEIN; HISTAMINE; ISOBUTYLMETHYLXANTHINE; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHODIESTERASE IV; RECEPTOR; ROLIPRAM; THEOPHYLLINE; TUMOR NECROSIS FACTOR ALPHA; XANTHINE DERIVATIVE;

AGING; ARTICLE; ASTHMA; BINDING AFFINITY; BRAIN TISSUE; CARDIOTOXICITY; DEPRESSION; DRUG DOSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; ENANTIOMER; ENZYME REGULATION; HEART FUNCTION; HEART INFARCTION; HUMAN; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; MENTAL DISEASE; NEUROLOGIC DISEASE; NONHUMAN; OBESITY; PHOSPHORYLATION; PLASMA PROTEIN BINDING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; SECOND MESSENGER; SMOOTH MUSCLE;

ANIMALS; ASTHMA; BRAIN; CARBON RADIOISOTOPES; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; HAPLORHINI; HUMANS; INFLAMMATION; MENTAL DISORDERS; MYOCARDIUM; NERVOUS SYSTEM DISEASES; OBESITY; PHOSPHODIESTERASE 4 INHIBITORS; POSITRON-EMISSION TOMOGRAPHY; RATS; ROLIPRAM; SIGNAL TRANSDUCTION; SWINE;

EID: 79955676372     PISSN: 18744710     EISSN: None     Source Type: Journal    
DOI: 10.2174/1874471011104010044     Document Type: Article

References (170)

1. Beavo, J.A.; Brunton, L.L. Cyclic nucleotide research - still expandingafter half a century. Nat. Rev. Mol. Cell Biol., 2002, 3(9),710-718.
2. Bristow, M.R.; Hershberger, R.E.; Port, J.D.; Minobe, W.; Rasmussen, R. Beta 1- and beta 2-adrenergic receptor-mediated adenylatecyclase stimulation in nonfailing and failing human ventricularmyocardium. Mol. Pharmacol., 1989, 35(3), 295-303.
3. Zhao, Y.; Zhang, H.T.; O'Donnell, J.M. Inhibitor binding to type 4phosphodiesterase (PDE4) assessed using [3H]piclamilast and[3H]rolipram. J. Pharmacol. Exp. Ther., 2003, 305(2), 565-572.
4. Liu, S.; Laliberte, F.; Bobechko, B.; Bartlett, A.; Lario, P.; Gorseth, E.; Van Hamme, J.; Gresser, M.J.; Huang, Z. Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors. Biochemistry,2001, 40(34), 10179-10186.
5. Laliberte, F.; Liu, S.; Gorseth, E.; Bobechko, B.; Bartlett, A.; Lario, P.; Gresser, M.J.; Huang, Z. In vitro PKA phosphorylationmediated human PDE4A4 activation. FEBS Lett., 2002, 512(1-3),205-208.
6. Davis, R.L.; Takayasu, H.; Eberwine, M.; Myres, J. Cloning andcharacterization of mammalian homologs of the Drosophila dunce+gene. Proc. Natl. Acad. Sci. USA, 1989, 86, 3604-3608.
7. Conti, M.; Jin, S.L. The molecular biology of cyclic nucleotidephosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol., 1999, 63,1-38.
8. Conti, M.; Beavo, J. Biochemistry and physiology of cyclic nucleotidephosphodiesterases: essential components in cyclic nucleotidesignaling. Annu. Rev. Biochem., 2007, 76, 481-511.
9. Beavo, J.A. Cyclic nucleotide phosphodiesterases: functional implicationsof multiple isoforms. Physiol. Rev., 1995, 75(4), 725-748.
10. Esposito, K.; Reierson, G.W.; Luo, H.R.; Wu, G.S.; Licinio, J.; Wong, M.L. Phosphodiesterase genes and antidepressant treatmentresponse: a review. Ann. Med., 2009, 41(3), 177-185.
11. Houslay, M.D.; Adams, D.R. PDE4 cAMP phosphodiesterases:modular enzymes that orchestrate signalling cross-talk, desensitizationand compartmentalization. Biochem. J., 2003, 370(Pt 1), 1-18.
12. Wong, M.L.; Whelan, F.; Deloukas, P.; Whittaker, P.; Delgado, M.; Cantor, R.M.; McCann, S.M.; Licinio, J. Phosphodiesterase genesare associated with susceptibility to major depression and antidepressanttreatment response. Proc. Natl. Acad. Sci. U S A, 2006,103(41), 15124-15129.
13. Zhang, H.T. Cyclic AMP-specific phosphodiesterase-4 as a targetfor the development of antidepressant drugs. Curr. Pharm. Des.,2009, 15(14), 1688-1698.
14. Torphy, T.J. Phosphodiesterase isozymes: molecular targets fornovel antiasthma agents. Am. J. Respir. Crit. Care. Med., 1998,157(2), 351-370.
15. Lamb, T.D.; Pugh, E.N., Jr. Phototransduction, dark adaptation,and rhodopsin regeneration: the proctor lecture. Invest. Ophthalmol.Vis. Sci., 2006, 47(12), 5137-5152.
16. Borisy, F.F.; Hwang, P.N.; Ronnett, G.V.; Snyder, S.H. HighaffinitycAMP phosphodiesterase and adenosine localized in sensoryorgans. Brain Res., 1993, 610, 199-207.
17. Moreland, R.B.; Goldstein, I.; Traish, A. Sildenafil, a novel inhibitorof phosphodiesterase type 5 in human corpus cavernosumsmooth muscle cells. Life Sci., 1998, 62(20), 309-318.
18. Sturton, G.; Fitzgerald, M. Phosphodiesterase 4 inhibitors for thetreatment of COPD. Chest, 2002, 121(5), 192S-196S.
19. Reneerkens, O.A.; Rutten, K.; Steinbusch, H.W.; Blokland, A.; Prickaerts, J. Selective phosphodiesterase inhibitors: a promisingtarget for cognition enhancement. Psychopharmacology (Berl.),2009, 202(1-3), 419-443.
20. Monti, B.; Berteotti, C.; Contestabile, A. Subchronic rolipramdelivery activates hippocampal CREB and arc, enhances retentionand slows down extinction of conditioned fear. Neuropsychopharmacology,2006, 31(2), 278-286.
21. Barad, M.; Bourtchouladze, R.; Winder, D.G.; Golan, H.; Kandel, E. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitatesthe establishment of long-lasting long-term potentiation andimproves memory. Proc. Natl. Acad. Sci. U S A, 1998, 95(25),15020-15025.
22. Weishaar, R.E.; Cain, M.H.; Bristol, J.A. A new generation ofphosphodiesterase inhibitors: multiple molecular forms of phosphodiesteraseand the potential for drug selectivity. J. Med. Chem.,1985, 28(5), 537-545.
23. Barnette, M.S.; Christensen, S.B.; Essayan, D.M.; Grous, M.; Prabhakar, U.; Rush, J.A.; Kagey-Sobotka, A.; Torphy, T.J. SB207499 (Ariflo), a potent and selective second-generation phosphodiesterase4 inhibitor: in vitro anti-inflammatory actions. J.Pharmacol. Exp. Ther., 1998, 284(1), 420-426.
24. Shah, D.I.; Singh, M. Activation of protein kinase A improvesvascular endothelial dysfunction. Endothelium, 2006, 13(4), 267-277.
25. Zeller, E.; Stief, H.-J.; Pflug, B.; Sastre-y-Hernández, M. Results ofa phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry,1984, 17, 188-190.
26. Bertolino, A.; Crippa, D.; di Dio, S.; Fichte, K.; Musmeci, G.; Porro, V.; Rapisarda, V.; Sastre-y-Hernandez, M.; Schratzer, M. Rolipram versus imipramine in inpatients with major, minor oratypical depressive disorder: a double-blind double-dummy studyaimed at testing a novel therapeutic approach. Int. Clin. Psychopharmacol.,1988, 3(3), 245-253.
27. Houslay, M.D.; Schafer, P.; Zhang, K.Y. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov. Today, 2005,10(22), 1503-1519.
28. Gretarsdottir, S.; Thorleifsson, G.; Reynisdottir, S.T.; Manolescu, A.; Jonsdottir, S.; Jonsdottir, T.; Gudmundsdottir, T.; Bjarnadottir, S.M.; Einarsson, O.B.; Gudjonsdottir, H.M.; Hawkins, M.; Gudmundsson, G.; Gudmundsdottir, H.; Andrason, H.; Gudmundsdottir, A.S.; Sigurdardottir, M.; Chou, T.T.; Nahmias, J.; Goss, S.; Sveinbjornsdottir, S.; Valdimarsson, E.M.; Jakobsson, F.; Agnarsson, U.; Gudnason, V.; Thorgeirsson, G.; Fingerle, J.; Gurney, M.; Gudbjartsson, D.; Frigge, M.L.; Kong, A.; Stefansson, K.; Gulcher, J.R. The gene encoding phosphodiesterase 4D confers risk ofischemic stroke. Nat. Genet., 2003, 35(2), 131-138.
29. Rao, Y.J.; Xi, L. Pivotal effects of phosphodiesterase inhibitors onmyocyte contractility and viability in normal and ischemic hearts.Acta Pharmacol. Sin., 2009, 30(1), 1-24.
30. Houslay, M.D.; Scotland, G.; Erdogan, S.; Huston, E.; Mackenzie, S.; McCallum, J.F.; McPhee, I.; Pooley, L.; Rena, G.; Ross, A.; Beard, M.; Peder, A.; Begg, F.; Wilkinson, I.; Yarwood, S.; Ackerman, C.; Houslay, E.S.; Hoffman, R.; Engels, P.; Sullivan, M.; Bolger, G. Intracellular targeting, interaction with Src homology 3(SH3) domains and rolipram-detected conformational switches incAMP-specific PDE4A phosphodiesterase. Biochem. Soc. Trans.,1997, 25(2), 374-381.
31. Houslay, M.D.; Baillie, G.S.; Maurice, D.H. cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a moleculartoolbox for generating compartmentalized cAMP signaling. Circ.Res., 2007, 100(7), 950-966.
32. Terry, R.; Cheung, Y.F.; Praestegaard, M.; Baillie, G.S.; Huston, E.; Gall, I.; Adams, D.R.; Houslay, M.D. Occupancy of the catalyticsite of the PDE4A4 cyclic AMP phosphodiesterase by rolipramtriggers the dynamic redistribution of this specific isoform inliving cells through a cyclic AMP independent process. Cell. Signal.,2003, 15(10), 955-971.
33. Jin, S.L.; Bushnik, T.; Lan, L.; Conti, M. Subcellular localizationof rolipram-sensitive, cAMP-specific phosphodiesterases. Differentialtargeting and activation of the splicing variants derived fromthe PDE4D gene. J. Biol. Chem., 1998, 273(31), 19672-19678.
34. Zaccolo, M.; Pozzan, T. Discrete microdomains with high concentrationof cAMP in stimulated rat neonatal cardiac myocytes. Science,2002, 295(5560), 1711-1715.
35. Bolger, G.B.; McCahill, A.; Huston, E.; Cheung, Y.F.; McSorley, T.; Baillie, G.S.; Houslay, M.D. The unique amino-terminal regionof the PDE4D5 cAMP phosphodiesterase isoform confers preferentialinteraction with beta-arrestins. J. Biol. Chem., 2003, 278(49),49230-49238.
36. Baillie, G.S.; Sood, A.; McPhee, I.; Gall, I.; Perry, S.J.; Lefkowitz, R.J.; Houslay, M.D. beta-Arrestin-mediated PDE4 cAMP phosphodiesteraserecruitment regulates beta-adrenoceptor switchingfrom Gs to Gi. Proc. Natl. Acad. Sci. USA, 2003, 100(3), 940-945.
37. Lynch, M.J.; Baillie, G.S.; Mohamed, A.; Li, X.; Maisonneuve, C.; Klussmann, E.; van Heeke, G.; Houslay, M.D. RNA silencing identifiesPDE4D5 as the functionally relevant cAMP phosphodiesteraseinteracting with beta arrestin to control the protein kinaseA/AKAP79-mediated switching of the beta2-adrenergic receptor toactivation of ERK in HEK293B2 cells. J. Biol. Chem., 2005,280(39), 33178-33189.
38. Perry, S.J.; Baillie, G.S.; Kohout, T.A.; McPhee, I.; Magiera, M.M.; Ang, K.L.; Miller, W.E.; McLean, A.J.; Conti, M.; Houslay, M.D.; Lefkowitz, R.J. Targeting of cyclic AMP degradation to beta2-adrenergic receptors by beta-arrestins. Science, 2002, 298(5594),834-836.
39. McLaughlin, M.M.; Cieslinski, L.B.; Burman, M.; Torphy, T.J.; Livi, G.P. A low-Km, rolipram-sensitive, cAMP-specific phosphodiesterasefrom human brain. J. Biol. Chem., 1993, 268(9),6470-6476.
40. Engels, P.; Fichtel, K.; Lübbert, H. Expression and regulation ofhuman and rat phosphodiesterase type IV isogenes. FEBS Lett.,1994, 350, 291-295.
41. Houslay, M.D.; Sullivan, M.; Bolger, G.B. The multienzyme PDE4cyclic adenosine monophosphate-specific phosphodiesterase family:intracellular targeting, regulation, and selective inhibition bycompounds exerting anti-inflammatory and antidepressant actions.Adv. Pharmacol., 1998, 44, 225-342.
42. Engels, P.; Abdel'Al, S.; Hulley, P.; Lübbert, H. Brain distributionof four rat homologues of the Drosophila dunce cAMP phosphodiesterase.J. Neurosci. Res., 1995, 41, 169-178.
43. Farooqui, S.M.; Zhang, K.; Makhay, M.; Jackson, K.; Farooqui, S.Q.; Cherry, J.A.; O'Donnell, J.M. Noradrenergic lesions differentiallyalter the expression of two subtypes of low Km cAMPsensitivephosphodiesterase type 4 (PDE4A and PDE4B) in ratbrain. Brain Res., 2000, 867(1-2), 52-61.
44. Iwahashi, Y.; Furuyama, T.; Tano, Y.; Ishimoto, I.; Shimomura, Y.; Inagaki, S. Differential distribution of mRNA encoding cAMPspecificphosphodiesterase isoforms in the rat brain. Brain Res.Mol. Brain Res., 1996, 38(1), 14-24.
45. Zhang, K.; Farooqui, S.M.; JM, O.D. Ontogeny of rolipramsensitive,low-K(m), cyclic AMP-specific phosphodiesterase in ratbrain. Brain Res. Dev. Brain Res., 1999, 112(1), 11-19.
46. Shakur, Y.; Wilson, M.; Pooley, L.; Lobban, M.; Griffiths, S.L.; Campbell, A.M.; Beattie, J.; Daly, C.; Houslay, M.D. Identificationand characterization of the type-ivA cyclic AMP-specific phosphodiesteraseRD1 as a membrane-bound protein expressed incerebellum. Biochem. J., 1995, 306, 801-809.
47. Richter, W.; Jin, S.L.; Conti, M. Splice variants of the cyclic nucleotidephosphodiesterase PDE4D are differentially expressed andregulated in rat tissue. Biochem. J., 2005, 388(Pt 3), 803-811.
48. D'Sa, C.; Eisch, A.J.; Bolger, G.B.; Duman, R.S. Differential expressionand regulation of the cAMP-selective phosphodiesterasetype 4A splice variants in rat brain by chronic antidepressant administration.Eur. J. Neurosci., 2005, 22(6), 1463-1475.
49. Kaulen, P.; Brüning, G.; Schneider, H.H.; Sarter, M.; Baumgarten,H.G. Autoradiographic mapping of selective cyclic adenosine monophosphatephosphodiesterase in rat brain with the antidepressant[3H] rolipram. Brain Res., 1989, 503, 229-245.
50. Dlaboga, D.; Hajjhussein, H.; O'Donnell, J.M. Chronic haloperidoland clozapine produce different patterns of effects on phosphodiesterase-1B, -4B, and -10A expression in rat striatum. Neuropharmacology,2008, 54(4), 745-754.
51. Bian, H.; Zhang, J.; Wu, P.; Varty, L.A.; Jia, Y.; Mayhood, T.; Hey, J.A.; Wang, P. Differential type 4 cAMP-specific phosphodiesterase(PDE4) expression and functional sensitivity to PDE4 inhibitorsamong rats, monkeys and humans. Biochem. Pharmacol.,2004, 68(11), 2229-2236.
52. Iona, S.; Cuomo, M.; Bushnik, T.; Naro, F.; Sette, C.; Hess, M.; Shelton, E.R.; Conti, M. Characterization of the rolipram-sensitive,cyclic AMP-specific phosphodiesterases: identification and differentialexpression of immunologically distinct forms in the rat brain. Mol. Pharmacol., 1998, 53(1), 23-32.
53. Bolger, G.B.; Rodgers, L.; Riggs, M. Differential CNS expressionof alternative mRNA isoforms of the mammalian genes encodingcAMP-specific phosphodiesterases. Gene, 1994, 149(2), 237-244.
54. Takahashi, M.; Terwilliger, R.; Lane, C.; Mezes, P.S.; Conti, M.; Duman, R.S. Chronic antidepressant administration increases theexpression of cAMP-specific phosphodiesterase 4A and 4B isoforms. J. Neurosci., 1999, 19, 610-618.
55. Abi-Gerges, A.; Richter, W.; Lefebvre, F.; Mateo, P.; Varin, A.; Heymes, C.; Samuel, J.L.; Lugnier, C.; Conti, M.; Fischmeister, R.; Vandecasteele, G. Decreased expression and activity of cAMPphosphodiesterases in cardiac hypertrophy and its impact on betaadrenergiccAMP signals. Circ. Res., 2009, 105(8), 784-792.
56. Kostic, M.M.; Erdogan, S.; Rena, G.; Borchert, G.; Hoch, B.; Bartel, S.; Scotland, G.; Huston, E.; Houslay, M.D.; Krause, E.G. Alteredexpression of PDE1 and PDE4 cyclic nucleotide phosphodiesteraseisoforms in 7-oxo-prostacyclin-preconditioned rat heart. J.Mol. Cell. Cardiol., 1997, 29(11), 3135-3146.
57. Takahashi, K.; Osanai, T.; Nakano, T.; Wakui, M.; Okumura, K. Enhanced activities and gene expression of phosphodiesterasetypes 3 and 4 in pressure-induced congestive heart failure. HeartVessels, 2002, 16(6), 249-256.
58. Kimura, M.; Tokumura, M.; Itoh, T.; Inoue, O.; Abe, K. Lack ofcyclic AMP-specific phosphodiesterase 4 activation duringnaloxone-precipitated morphine withdrawal in rats. Neurosci. Lett.,2006, 404(1-2), 107-111.
59. Chang, Y.-H.; Conti, M.; Lee, Y.-C.; Lai, H.-L.; Ching, Y.-H.; Chern, Y. Activation of phosphodiesterase IV during densensitizationof the A2A adenosine receptor-mediated cyclic AMP responsein rat pheochromocytoma (PC12) cells. J. Neurochem., 1997, 69,1300-1309.
60. Liu, H.; Maurice, D.H. Phosphorylation-mediated activation andtranslocation of the cyclic AMP-specific phosphodiesterasePDE4D3 by cyclic AMP-dependent protein kinase and mitogenactivatedprotein kinases. A potential mechanism allowing for thecoordinated regulation of PDE4D activity and targeting. J. Biol.Chem., 1999, 274(15), 10557-10565.
61. Sette, C.; Conti, M. Phosphorylation and activation of a cAMPspecificphosphodiesterase by the cAMP-dependent protein kinase.J. Biol. Chem., 1996, 271, 16526-16534.
62. Hoffmann, R.; Wilkinson, I.R.; McCallum, J.F.; Engels, P.; Houslay, M.D. cAmp-specific phosphodiesterase Hspde4d3 mutantswhich mimic activation and changes in rolipram inhibitiontriggered by protein kinase a phosphorylation of Ser-54: generationof a molecular model. Biochem. J., 1998, 333(Pt 1), 139-149.
63. Itoh, T.; Abe, K.; Hong, J.; Inoue, O.; Pike, V.W.; Innis, R.B.; Fujita, M. Effects of cAMP-dependent protein kinase activator andinhibitor on in vivo rolipram binding to phosphodiesterase 4 in consciousrats. Synapse, 2010, 64(2), 172-176.
64. Hoffmann, R.; Baillie, G.S.; MacKenzie, S.J.; Yarwood, S.J.; Houslay, M.D. The MAP kinase ERK2 inhibits the cyclic AMPspecificphosphodiesterase HSPDE4D3 by phosphorylating it atSer579. EMBO J., 1999, 18(4), 893-903.
65. Liu, H.; Palmer, D.; Jimmo, S.L.; Tilley, D.G.; Dunkerley, H.A.; Pang, S.C.; Maurice, D.H. Expression of phosphodiesterase 4D(PDE4D) is regulated by both the cyclic AMP-dependent proteinkinase and mitogen-activated protein kinase signaling pathways. Apotential mechanism allowing for the coordinated regulation ofPDE4D activity and expression in cells. J. Biol. Chem., 2000,275(34), 26615-26624.
66. Rose, R.J.; Liu, H.; Palmer, D.; Maurice, D.H. Cyclic AMPmediatedregulation of vascular smooth muscle cell cyclic AMPphosphodiesterase activity. Br. J. Pharmacol., 1997, 122(2), 233-240.
67. Tilley, D.G.; Maurice, D.H. Vascular smooth muscle cell phosphodiesterase(PDE) 3 and PDE4 activities and levels are regulatedby cyclic AMP in vivo. Mol. Pharmacol., 2002, 62(3), 497-506.
68. Torphy, T.J.; Zhou, H.-L.; Cieslinski, L.B. Stimulation of betaadrenoceptors in a human monocyte cell line (U937) up-regulatescyclic AMP-specific phosphodiesterase activity. J. Pharmacol.Exp. Ther., 1992, 263(3), 1195-1205.
69. Manning, C.D.; McLaughlin, M.M.; Livi, G.P.; Cieslinski, L.B.; Torphy, T.J.; Barnette, M.S. Prolonged beta adrenoceptor stimulationup-regulates cAMP phosphodiesterase activity in humanmonocytes by increasing mRNA and protein for phosphodiesterases4A and 4B. J. Pharmacol. Exp. Ther., 1996, 276(2), 810-818.
70. Campos-Toimil, M.; Keravis, T.; Orallo, F.; Takeda, K.; Lugnier, C. Short-term or long-term treatments with a phosphodiesterase-4(PDE4) inhibitor result in opposing agonist-induced Ca(2+) responsesin endothelial cells. Br. J. Pharmacol., 2008, 154(1), 82-92.
71. Erdogan, S.; Houslay, M.D. Challenge of human jurkat T-cells withthe adenylate cyclase activator forskolin elicits major changes incAMP phosphodiesterase (PDE) expression by up-regulating PDE3and inducing PDE4D1 and PDE4D2 splice variants as well asdown-regulating a novel PDE4A splice variant. Biochem. J., 1997,321, 165-175.
72. Tenor, H.; Schudt, C. In: Analysis of PDE Isoenzyme Profiles inCells and Tissues by Pharmacological Methods; Tenor, H.; Schudt,C., Ed.: Academic Press: San Diego, 1996; pp. 21-40.
73. Ye, Y.; O'Donnell, J.M. Diminished noradrenergic stimulationreduces the activity of rolipram-sensitive, high-affinity cyclic AMPphosphodiesterase in rat cerebral cortex. J. Neurochem., 1996, 66,1894-1902.
74. Ye, Y.; Conti, M.; Houslay, M.D.; Farooqui, S.M.; Chen, M.; O'Donnell, J.M. Noradrenergic activity differentially regulates theexpression of rolipram-sensitive, high-affinity cyclic AMP phosphodiesterase(PDE4) in rat brain. J. Neurochem., 1997, 69(6),2397-2404.
75. Yasui, K.; Komiyama, A. New clinical applications of xanthinederivatives: modulatory actions on leukocyte survival and function.Int. J. Hematol., 2001, 73(1), 87-92.
76. Wells, J.N.; Kramer, G.L. Phosphodiesterase inhibitors as tools incyclic nucleotide research: a precautionary comment. Mol. Cell.Endocrinol., 1981, 23(1), 1-9.
77. Wachtel, H. Characteristic behavioral alterations in rats induced byrolipram and other selective adenosine cyclic 3',5' -monophosphatephosphodiesterase inhibitors. Psychopharmacology, 1982, 77, 309-316.
78. Wachtel, H. Potential antidepressant activity of rolipram and otherselective cyclic adenosine 3',5'-monophosphate phosphodiesteraseinhibitors. Neuropharmacology, 1983, 22(3A), 267-272.
79. Wachtel, H. Neurotropic effects of the optical isomers of the selectiveadenosine cyclic 3',5'-monophosphate phosphodiesterase inhibitorrolipram in rats in-vivo. J. Pharm. Pharmacol., 1983, 35,440-444.
80. Wachtel, H. In: Defective Second-messenger Function in the Etiologyof Endogenous Depression: Novel Therapeutic Approaches;Wachtel, H., Ed.: MacMillan Press: Basingstoke, 1988; Vol. 2, pp.277-293
81. Manning, C.D.; Burman, M.; Christensen, S.B.; Cieslinski, L.B.; Essayan, D.M.; Grous, M.; Torphy, T.J.; Barnette, M.S. Suppressionof human inflammatory cell function by subtype-selectivePDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.Br. J. Pharmacol., 1999, 128(7), 1393-1398.
82. Pages, L.; Gavalda, A.; Lehner, M.D. PDE4 inhibitors: a review ofcurrent developments (2005 - 2009). Expert Opin. Ther. Pat., 2009,19(11), 1501-1519.
83. Kajimoto, K.; Hagiwara, N.; Kasanuki, H.; Hosoda, S. Contributionof phosphodiesterase isozymes to the regulation of the L-type calciumcurrent in human cardiac myocytes. Br. J. Pharmacol., 1997,121, 1549-1556.
84. Schneider, H.H.; Schmiechen, R.; Brezinski, M.; Seidler, J. Stereospecificbinding of the antidepressant rolipram to brain proteinstructures. Eur. J. Pharmacol., 1986, 127, 105-115.
85. Jacobitz, S.; Ryan, M.D.; McLaughlin, M.M.; Livi, G.P.; DeWolf, W.E.; Torphy, T.J. Role of conserved histidines in catalytic activityand inhibitor binding of human recombinant phosphodiesterase4A. Mol. Pharmacol., 1997, 51(6), 999-1006.
86. Zhao, Y.; Zhang, H.T.; O'Donnell, J.M. Antidepressant-inducedincrease in high-affinity rolipram binding sites in rat brain: dependenceon noradrenergic and serotonergic function. J. Pharmacol.Exp. Ther., 2003, 307(1), 246-253.
87. Torphy, T.J.; Stadel, J.M.; Burman, M.; Cieslinski, L.B.; McLaughlin, M.M.; White, J.R.; Livi, G.P. Coexpression of humancAMP-specific phosphodiesterase activity and high affinity roliprambinding in yeast. J. Biol. Chem., 1992, 267(3), 1798-1804.
88. Jacobitz, S.; McLaughlin, M.M.; Livi, G.P.; Burman, M.; Torphy, T.J. Mapping the functional domains of human recombinant phosphodiesterase4A: structural requirements for catalytic activity androlipram binding. Mol. Pharmacol., 1996, 50(4), 891-899.
89. Barnette, M.S.; Grous, M.; Cieslinski, L.B.; Burman, M.; Christensen, S.B.; Torphy, T.J. Inhibitors of phosphodiesterase IV (PDEIV) increase acid secretion in rabbit isolated gastric glands: correlationbetween function and interaction with a high-affinity roliprambinding site. J. Pharmacol. Exp. Ther., 1995, 273(3), 1396-1402.
90. Barnette, M.S.; Bartus, J.O.; Burman, M.; Christensen, S.B.; Cieslinski, L.B.; Esser, K.M.; Prabhakar, U.S.; Rush, J.A.; Torphy, T.J. Association of the anti-inflammatory activity of phosphodiesterase4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activityor competition for [3H]rolipram binding. Biochem. Pharmacol.,1996, 51(7), 949-956.
91. Kelly, J.J.; Barnes, P.J.; Giembycz, M.A. Phosphodiesterase 4 inmacrophages: relationship between cAMP accumulation, suppressionof cAMP hydrolysis and inhibition of [3H]R-(-)-roliprambinding by selective inhibitors. Biochem. J., 1996, 318(Pt 2), 425-436.
92. Xu, R.X.; Hassell, A.M.; Vanderwall, D.; Lambert, M.H.; Holmes, W.D.; Luther, M.A.; Rocque, W.J.; Milburn, M.V.; Zhao, Y.; Ke, H.; Nolte, R.T. Atomic structure of PDE4: insights into phosphodiesterasemechanism and specificity. Science, 2000, 288(5472),1822-1825.
93. Makhlouf, A.; Kshirsagar, A.; Niederberger, C. Phosphodiesterase11: a brief review of structure, expression and function. Int. J. Impot.Res., 2006, 18(6), 501-509.
94. Duman, R.S.; Heninger, G.R.; Nestler, E.J. A molecular and cellulartheory of depression. Arch. Gen. Psychiatry, 1997, 54, 597-606.
95. Lourenco, C.M.; Kenk, M.; Beanlands, R.S.; DaSilva, J.N. Increasingsynaptic noradrenaline, serotonin and histamine enhances invivo binding of phosphodiesterase-4 inhibitor (R)-[11C]rolipram inrat brain, lung and heart. Life Sci., 2006, 79(4), 356-364.
96. ] Delgado, M.; Fuentes, J.A.; Fernandez-Alfonso, M.S. Histamineup-regulates phosphodiesterase IV activity in U-937 cells throughH2 receptor stimulation and cAMP increase. Med. Sci. Monit.,2003, 9(6), 252-259.
97. Wachtel, H.; Schneider, H.H. Rolipram, a novel antidepressantdrug, reverses the hypothermia and hypokinesia of monoaminedepletedmice by an action beyond postsynaptic monoamine receptors. Neuropharmacology, 1986, 25(10), 1119-1126.
98. O'Donnell, J.M.; Zhang, H.T. Antidepressant effects of inhibitorsof cAMP phosphodiesterase (PDE4). Trends Pharmacol. Sci.,2004, 25(3), 158-163.
99. Itoh, T.; Tokumura, M.; Abe, K. Effects of rolipram, a phosphodiesterase4 inhibitor, in combination with imipramine on depressivebehavior, CRE-binding activity and BDNF level in learned helplessnessrats. Eur. J. Pharmacol., 2004, 498(1-3), 135-142.
100. Itoh, T.; Abe, K.; Tokumura, M.; Horiuchi, M.; Inoue, O.; Ibii, N. Different regulation of adenylyl cyclase and rolipram-sensitivephosphodiesterase activity on the frontal cortex and hippocampusin learned helplessness rats. Brain Res., 2003, 991(1-2), 142-149.
101. Cho, C.H.; Cho, D.H.; Seo, M.R.; Juhnn, Y.S. Differential changesin the expression of cyclic nucleotide phosphodiesterase isoformsin rat brains by chronic treatment with electroconvulsive shock. Exp. Mol. Med., 2000, 32(3), 110-114.
102. Takahashi, M.; Terwilliger, R.; Lane, C.; Mezes, P.S.; Conti, M.; Duman, R.S. Chronic antidepressant administration increases theexpression of cAMP-specific phosphodiesterase 4A and 4B isoforms. J. Neurosci., 1999, 19(2), 610-618.
103. Vecsey, C.G.; Baillie, G.S.; Jaganath, D.; Havekes, R.; Daniels, A.; Wimmer, M.; Huang, T.; Brown, K.M.; Li, X.Y.; Descalzi, G.; Kim, S.S.; Chen, T.; Shang, Y.Z.; Zhuo, M.; Houslay, M.D.; Abel, T. Sleep deprivation impairs cAMP signalling in the hippocampus. Nature, 2009, 461(7267), 1122-1125.
104. Fujita, M.; Innis, R.B. Nuclear psychiatry: specialty for the twentyfirstcentury? Eur. J. Nucl. Med., 2000, 27(1 Suppl), 39-42.
105. Mongillo, M.; McSorley, T.; Evellin, S.; Sood, A.; Lissandron, V.; Terrin, A.; Huston, E.; Hannawacker, A.; Lohse, M.J.; Pozzan, T.; Houslay, M.D.; Zaccolo, M. Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiacmyocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ. Res., 2004, 95(1), 67-75.
106. Mongillo, M.; Tocchetti, C.G.; Terrin, A.; Lissandron, V.; Cheung, Y.F.; Dostmann, W.R.; Pozzan, T.; Kass, D.A.; Paolocci, N.; Houslay, M.D.; Zaccolo, M. Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via anNO/cGMP-dependent pathway. Circ. Res., 2006, 98(2), 226-234.
107. Nikolaev, V.O.; Bunemann, M.; Schmitteckert, E.; Lohse, M.J.; Engelhardt, S. Cyclic AMP imaging in adult cardiac myocytes revealsfar-reaching beta1-adrenergic but locally confined beta2-adrenergic receptor-mediated signaling. Circ. Res., 2006, 99(10),1084-1091.
108. Katano, Y.; Endoh, M. Effects of a cardiotonic quinolinone derivativeY-20487 on the isoproterenol-induced positive inotropic actionand cyclic AMP accumulation if rat ventricular myocardium: comparisonwith rolipram, Ro 20-1724, milrinone, and isobutylmethylxanthine.J. Cardiovasc. Pharmacol., 1992, 20, 715-722.
109. Katano, Y.; Endoh, M. Differential effects of Ro 20-1724 andisobutylmethylxanthine on the basal force of contraction and betaadrenoceptor-mediated response in the rat ventricular myocardium. Biochem. Biophys. Res. Commun., 1990, 167(1), 123-129.
110. Xiang, Y.; Kobilka, B.K. Myocyte adrenoceptor signaling pathways.Science, 2003, 300(5625), 1530-1532.
111. Cui, H.; Green, R.D. Regulation of the cAMP-elevating effects ofisoproterenol and forskolin in cardiac myocytes by treatments thatcause increases in cAMP. Biochem. Biophys. Res. Commun., 2003,307(1), 119-126.
112. Leimbach, W.N., Jr.; Wallin, B.G.; Victor, R.G.; Aylward, P.E.; Sundlof, G.; Mark, A.L. Direct evidence from intraneural recordingsfor increased central sympathetic outflow in patients withheart failure. Circulation, 1986, 73(5), 913-919.
113. Eisenhofer, G.; Friberg, P.; Rundqvist, B.; Quyyumi, A.A.; Lambert, G.; Kaye, D.M.; Kopin, I.J.; Goldstein, D.S.; Esler, M.D. Cardiac sympathetic nerve function in congestive heart failure. Circulation,1996, 93(9), 1667-1676.
114. Osadchii, O.; Norton, G.; Deftereos, D.; Woodiwiss, A. Rat strainrelateddifferences in myocardial adrenergic tone and the impact oncardiac fibrosis, adrenergic responsiveness and myocardial structureand function. Pharmacol. Res., 2007, 55(4), 287-294.
115. Lehnart, S.E.; Wehrens, X.H.; Reiken, S.; Warrier, S.; Belevych, A.E.; Harvey, R.D.; Richter, W.; Jin, S.L.; Conti, M.; Marks, A.R. Phosphodiesterase 4D deficiency in the ryanodine-receptor complexpromotes heart failure and arrhythmias. Cell, 2005, 123(1),25-35.
116. DaSilva, J.N.; Valente, C.M.; Wilson, A.A.; Warsh, J.J.; Houle, S. Carbon-11 labeling of the selective inhibitors of phosphodiesterase-IV Ro 20-1724 and rolipram. J. Label. Compd. Radiopharm., 1997,40, 678-680.
117. Lourenco, C.M.; DaSilva, J.N.; Warsh, J.J.; Wilson, A.A.; Houle, S. Imaging of cAMP-specific phosphodiesterase-IV: comparison of[11C]rolipram and [11C]Ro 20-1724 in rats. Synapse, 1999, 31(1),41-50.
118. DaSilva, J.N.; Lourenco, C.M.; Wilson, A.A.; Houle, S. Synthesesof the phosphodiesterase-4 inhibitors [11C]Ro 20-1724, R-, R/S- andS-[11C]rolipram. J. Label. Compd. Radiopharm., 2001, 44(5), 373-384.
119. Fujita, M.; Zoghbi, S.S.; Crescenzo, M.S.; Hong, J.; Musachio, J.L.; Lu, J.Q.; Liow, J.S.; Seneca, N.; Tipre, D.N.; Cropley, V.L.; Imaizumi, M.; Gee, A.D.; Seidel, J.; Green, M.V.; Pike, V.W.; Innis, R.B. Quantification of brain phosphodiesterase 4 in rat with(R)-[(11)C]Rolipram-PET. Neuroimage, 2005, 26(4), 1201-1210.
120. Parker, C.A.; Matthews, J.C.; Gunn, R.N.; Martarello, L.; Cunningham, V.J.; Dommett, D.; Knibb, S.T.; Bender, D.; Jakobsen, S.; Brown, J.; Gee, A.D. Behaviour of [(11)C]R(-)- and[(11)C]S(+)-rolipram in vitro and in vivo, and their use as PET radiotracersfor the quantificative assay of PDE4. Synapse, 2005,55(4), 270-279.
121. Tsukada, H.; Harada, N.; Ohba, H.; Nishiyama, S.; Kakiuchi, T. Facilitation of dopaminergic neural transmission does not affect[(11)C]SCH23390 binding to the striatal D(1) dopamine receptors,but the facilitation enhances phosphodiesterase type-IV activitythrough D(1) receptors: PET studies in the conscious monkeybrain. Synapse, 2001, 42(4), 258-265.
122. Fujita, M.; Imaizumi, M.; D'Sa, C.; Zoghbi, S.S.; Crescenzo, M.S.; Hong, J.; Musachio, J.L.; Gee, A.D.; Seidel, J.; Green, M.V.; Pike, V.W.; Duman, R.S.; Innis, R.B. In vivo and in vitro measurementof brain phosphodiesterase 4 in rats after antidepressant administration. Synapse, 2007, 61(2), 78-86.
123. Kenk, M.; Greene, M.; Thackeray, J.; Dekemp, R.A.; Lortie, M.; Thorn, S.; Beanlands, R.S.; Dasilva, J.N. In vivo selective bindingof (R)-[(11)C]rolipram to phosphodiesterase-4 provides the basisfor studying intracellular cAMP signaling in the myocardium andother peripheral tissues. Nucl. Med. Biol., 2007, 34(1), 71-77.
124. DaSilva, J.N.; Lourenco, C.M.; Meyer, J.H.; Hussey, D.; Potter, W.Z.; Houle, S. Imaging cAMP-specific phosphodiesterase-4 inhuman brain with (R)-[11C]rolipram and positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging, 2002, 29(12), 1680-1683.
125. Heaslip, R.J.; Evans, D.Y. Emetic, central nervous system andpulmonary activities of rolipram in the dog. Eur. J. Pharmacol.,1995, 286, 281-190.
126. Sprague, D.R.; Fujita, M.; Ryu, Y.H.; Liow, J.S.; Pike, V.W.; Innis, R.B. Whole-body biodistribution and radiation dosimetry in monkeysand humans of the phosphodiesterase 4 radioligand[(11)C](R)-rolipram: comparison of two-dimensional planar, bisectedand quadrisected image analyses. Nucl. Med. Biol., 2008,35(4), 493-500.
127. Lourenco, C.M.; Houle, S.; Wilson, A.A.; DaSilva, J.N. Characterizationof (R)-[11C]rolipram for PET imaging of phosphodiesterase-4: in vivo binding, metabolism, and dosimetry studies inrats. Nucl. Med. Biol., 2001, 28(4), 347-358.
128. International commission on radiological protection. Annex C:Biokinetic models and dose tables. Ann. ICRP, 2008, 38(1-2), 51-162.
129. Krause, W.; Kühne, G.; Matthes, H. Pharmacokinetics of the antidepressantrolipram in healthy volunteers. Xenobiotica, 1989,19(6), 683-692.
130. Krause, W.; Kühne, G. Pharmacokinetics of rolipram in the rhesusand cynomolgus monkeys, the rat and the rabbit. Studies on speciesdifferences. Xenobiotica, 1988, 18(5), 561-571.
131. Krause, W.; Kühne, G. Biotransformation of the antidepressantD,L-rolipram. II. Metabolite patterns in man, rat, rabbit, rehesusand cynomolgus monkey. Xenobiotica, 1993, 23(11), 1277-1288.
132. Krause, W.; Kühne, G. High-performance liquid chromatographicprocedure for specificity testing of radioimmunoassays: rolipram.J. Chromatogr., 1992, 573, 303-308.
133. Davis, C.W.; Daly, J.W. A simple direct assay of 3',5'-cyclic nucleotidephosphodiesterase activity based on the use of polyacrylamide-boronate affinity gel chromatography. J. Cycl. NucleotideRes., 1979, 5(1), 65-74.
134. Kenk, M.; Greene, M.; Lortie, M.; Dekemp, R.A.; Beanlands, R.S.; Dasilva, J.N. Use of a column-switching high-performance liquidchromatography method to assess the presence of specific bindingof (R)- and (S)-[(11)C]rolipram and their labeled metabolites to thephosphodiesterase-4 enzyme in rat plasma and tissues. Nucl. Med.Biol., 2008, 35(4), 515-521.
135. DaSilva, J.N.; Lourenco, C.M.; Meyer, J.H.; Hussey, D.; Potter, W.Z.; Houle, S. Imaging cAMP-specific phosphodiesterase-4 inhuman brain with R-[11C]rolipram and positron emission tomography. Eur. J. Nuc. Med. Mol. Imaging, 2002, 29(12), 1680-1683.
136. Pike, V.W. PET radiotracers: crossing the blood-brain barrier andsurviving metabolism. Trends Pharmacol. Sci., 2009, 30(8), 431-440.
137. Lortie, M.; DaSilva, J.; Kenk, M.; Thorn, S.; Beanlands, R.; deKemp, R. Kinetics of (R)-[11C]Rolipram and (S)-[11C]Rolipram in the Dog Heart: Investigation of Four CompartmentModels. IEEE Medical Imaging Conference. San Diego, California,2006, p. A274.
138. Itoh, T.; Abe, K.; Zoghbi, S.S.; Inoue, O.; Hong, J.; Imaizumi, M.; Pike, V.W.; Innis, R.B.; Fujita, M. PET measurement of the in vivoaffinity of 11C-(R)-rolipram and the density of its target, phosphodiesterase-4, in the brains of conscious and anesthetized rats. J.Nucl. Med., 2009, 50(5), 749-756.
139. Tsukada, H.; Kakiuchi, T.; Nishiyama, S.; Ohba, H.; Harada, N. Effects of aging on 5-HT(1A) receptors and their functional responseto 5-HT(1a) agonist in the living brain: PET study with[carbonyl-(11)C]WAY-100635 in conscious monkeys. Synapse,2001, 42(4), 242-251.
140. Harada, N.; Nishiyama, S.; Ohba, H.; Sato, K.; Kakiuchi, T.; Tsukada, H. Age differences in phosphodiesterase type-IV and itsfunctional response to dopamine D1 receptor modulation in the livingbrain: a PET study in conscious monkeys. Synapse, 2002,44(3), 139-145.
141. Gee, A.; Parker, C.; Matthews, J.; Passchier, J.; Smith, D.; Bender, D.; Knibb, S.; Gjedde, A.; Brown, J. Evidence to support the use ofS(+)-[11C]Rolipram in estimating the non-specific binding componentof R(-)-[11C]Rolipram to PDE4 in vivo using PET. NeuroImage,2002, 16(3), S34.
142. Thomas A.J.; Renaud, J.M.; Lortie, M.; Kenk, M.; Beanlands, R.S.; DaSilva, J.N.; deKemp, R.A. In vivo characterization of (R)-[11C]Rolipram PDE4-specific binding in rat heart using small animal PET. J. Nucl. Med., 2011, 52(2), 263-269.
143. Hume, S.P.; Gunn, R.N.; Jones, T. Pharmacological constraintsassociated with positron emission tomographic scanning of smalllaboratory animals. Eur. J. Nucl. Med., 1998, 25(2), 173-176.
144. Harada, N.; Nishiyama, S.; Ohba, H.; Sato, K.; Kakiuchi, T.; Tsukada, H. Age differences in phosphodiesterase type-IV and itsfunctional response to dopamine D1 receptor modulation in the livingbrain: a PET study in conscious monkeys. Synapse, 2002,44(3), 139-145.
145. Ye, Y.; Jackson, K.; O'Donnell, J.M. Effects of repeated antidepressanttreatment of type 4A phosphodiesterase (PDE4A) in ratbrain. J. Neurochem., 2000, 74(3), 1257-1262.
146. Collins, S.; Surwit, R.S. The beta-adrenergic receptors and thecontrol of adipose tissue metabolism and thermogenesis. Recent Prog. Horm. Res., 2001, 56, 309-328.
147. Dulloo, A.G. Biomedicine. A sympathetic defense against obesity.Science, 2002, 297(5582), 780-781.
148. Landsberg, L. Diet, obesity and hypertension: an hypothesis involvinginsulin, the sympathetic nervous system, and adaptive thermogenesis. Q. J. Med., 1986, 61(236), 1081-1090.
149. Levin, B.E.; Dunn-Meynell, A.A.; Balkan, B.; Keesey, R.E. Selectivebreeding for diet-induced obesity and resistance in Sprague-Dawley rats. Am. J. Physiol., 1997, 273(2 Pt 2), 725-730.
150. Levin, B.E.; Dunn-Meynell, A.A. Defense of body weight againstchronic caloric restriction in obesity-prone and -resistant rats. Am.J. Physiol. Regul. Integr. Comp. Physiol., 2000, 278(1), 231-237.
151. Levin, B.E.; Triscari, J.; Sullivan, A.C. Altered sympathetic activityduring development of diet-induced obesity in rat. Am. J.Physiol., 1983, 244(3), 347-355.
152. Greene, M.; Thackeray, J.T.; Kenk, M.; Thorn, S.L.; Bevilacqua, L.; Harper, M.-E.; Beanlands, R.S.; DaSilva, J.N. Reduced In vivoPhosphodiesterase-4 Response to Norepinephrine Challenge inDiet-Induced Obese Rats. Can. J. Physiol. Pharmacol., 2009,87,196-202.
153. Lefrak, E.A.; Pitha, J.; Rosenheim, S.; Gottlieb, J.A. A clinicopathologicanalysis of adriamycin cardiotoxicity. Cancer, 1973,32(2), 302-314.
154. Tong, J.; Ganguly, P.K.; Singal, P.K. Myocardial adrenergicchanges at two stages of heart failure due to adriamycin treatmentin rats. Am. J. Physiol., 1991, 260(3 Pt 2), 909-916.
155. Kenk, M.; Thackeray, J.T.; Thorn, S.L.; Dhami, K.; Chow, B.J.; Ascah, K.J.; Dasilva, J.N.; Beanlands, R.S. Alterations of pre- andpostsynaptic noradrenergic signaling in a rat model of adriamycininducedcardiotoxicity. J. Nucl. Cardiol., 2010, 17(2), 175-176.
156. Kenk, M.; Thorn, S.L.; Renaud, J.M.; Kolajova, M.; Klein, R.; Lamoureux, M.; DeKemp, R.A.; Beanlands, R.S.; DaSilva, J.N. Reduced beta1-adrenergic receptor expression is associated withincreased phosphodiesterase-4 inhibitor (R)-[11C]rolipram retentionin normally-perfused myocardium 8 weeks following myocardialinfarction. Circ. Cardiovasc. Imaging (In submission).
157. Kenk, M.; Thorn, S.; Thomas, A.J.; Renaud, J.M.; Klein, R.; Lortie, M.; deKemp, R.; Beanlands, R.S.; DaSilva, J.N. In vivo (R)-[11C]Rolipram positron emission tomography imaging detects increasedphosphodiesterase-4 in normally-perfused rat myocardialregions 8-12 weeks following myocardial infarction. Circulation,2010, 122(21 Supplement), A20262.
158. Sasaki, T.; Enta, A.; Nozaki, T.; Ishii, S.; Senda, M. Carbon-11-forskolin: a ligand for visualization of the adenylate cyclase-relatedsecond messenger system. J. Nucl. Med., 1993, 34(11), 1944-1948.
159. Kiesewetter, D.O.; Sassaman, M.B.; Robbins, J.; Elaine, M.J.; Carson, R.E.; Appel, N.M.; Sutkowski, E.; Herscovitch, P.; Braun, A.; Eckelman, W.C. Synthesis and evaluation of an 18F analog offorskolin for imaging adenylyl cyclase. J. Fluorine Chem., 2000,101, 297-304.
160. Vasdev, N.; LaRonde, F.J.; Woodgett, J.R.; Garcia, A.; Rubie, E.A.; Meyer, J.H.; Houle, S.; Wilson, A.A. Rationally designedPKA inhibitors for positron emission tomography: Synthesis andcerebral biodistribution of N-(2-(4-bromocinnamylamino)ethyl)-N-[11C]methyl-isoquinoline-5-sulfonamide. Bioorg. Med. Chem.,2008, 16(9), 5277-5284.
161. Otani, H.; Kagaya, Y.; Imahori, Y.; Yasuda, S.; Fujii, R.; Chida, M.; Namiuchi, S.; Takeda, M.; Sakuma, M.; Watanabe, J.; Ido, T.; Nonogi, H.; Shirato, K. Myocardial 11C-diacylglycerol accumulationand left ventricular remodeling in patients after myocardial infarction. J. Nucl. Med., 2005, 46(4), 553-559.
162. Chida, M.; Kagaya, Y.; Imahori, Y.; Namiuchi, S.; Fujii, R.; Fukuchi, M.; Takahashi, C.; Tezuka, F.; Ido, T.; Shirato, K. Visualizationof myocardial phosphoinositide turnover with 1-[1-(11)C]-butyryl-2-palmitoyl-rac-glycerol in rats with myocardial infarction. J. Nucl. Med., 2000, 41(12), 2063-2068.
163. Sasaki, T.; Ishii, S.-I.; Senda, M.; Akinaga, S.; Murakata, C. Synthesis of [7ß-methoxy 11C]methoxy staurosporine for imaging proteinkinase C localization in the brain. Appl. Radiat. Isot., 1996,47(1), 67-69.
164. Ohmori, Y.; Imahori, Y.; Ueda, S.; Fujii, R.; Ido, T.; Wakita, K.; Nakahashi, H. Protein kinase C imaging using carbon-11-labeledphorbol esters: 12-deoxyphorbol 13-isobutyrate-20-[1-11C]butyrate as the potential ligand for positron emission tomography. J. Nucl. Med., 1993, 34(3), 431-439.
165. Rena, G.; Begg, F.; Ross, A.; MacKenzie, C.; McPhee, I.; Campbell, L.; Huston, E.; Sullivan, M.; Houslay, M.D. Molecular cloning,genomic positioning, promoter identification, and characterizationof the novel cyclic amp-specific phosphodiesterase PDE4A10. Mol. Pharmacol., 2001, 59(5), 996-1011.
166. Shepherd, M.; McSorley, T.; Olsen, A.E.; Johnston, L.A.; Thomson, N.C.; Baillie, G.S.; Houslay, M.D.; Bolger, G.B. Molecularcloning and subcellular distribution of the novel PDE4B4 cAMPspecificphosphodiesterase isoform. Biochem. J., 2003, 370(2),429-438.
167. Cheung, Y.F.; Kan, Z.; Garrett-Engele, P.; Gall, I.; Murdoch, H.; Baillie, G.S.; Camargo, L.M.; Johnson, J.M.; Houslay, M.D.; Castle, J.C. PDE4B5, a novel, super-short, brain-specific cAMP phosphodiesterase-4 variant whose isoform-specifying N-terminal regionis identical to that of cAMP phosphodiesterase-4D6(PDE4D6). J. Pharmacol. Exp. Ther., 2007, 322(2), 600-609.
168. Owens, R.J.; Lumb, S.; Rees-Milton, K.; Russell, A.; Baldock, D.; Lang, V.; Crabbe, T.; Ballesteros, M.; Perry, M.J. Molecular cloningand expression of a human phosphodiesterase 4C. Cell. Signal.,1997, 9(8), 575-585.
169. Bolger, G.B.; Erdogan, S.; Jones, R.E.; Loughney, K.; Scotland, G.; Hoffmann, R.; Wilkinson, I.; Farrell, C.; Houslay, M.D. Characterizationof five different proteins produced by alternativelyspliced mRNAs from the human cAMP-specific phosphodiesterasePDE4D gene. Biochem. J., 1997, 328(2), 539-548.
170. Chandrasekaran, A.; Toh, K.Y.; Low, S.H.; Tay, S.K.; Brenner, S.; Goh, D.L. Identification and characterization of novel mousePDE4D isoforms: molecular cloning, subcellular distribution anddetection of isoform-specific intracellular localization signals. Cell.Signal., 2008, 20(1), 139-153.